MedPath

Efficacy and safety of administration of vonoprazan after endoscopic submucosal dissection (ESD) for gastric adenoma/carcinoma

Not Applicable
Conditions
Gastric adenoma/carcinoma
Registration Number
JPRN-UMIN000018169
Lead Sponsor
Chiba University
Brief Summary

lcer contraction rate at 4 weeks after ESD in the vonoprazan group was significantly higher than that of the esomeprazole group (97.7 +- 3.2% vs 94.5 +- 6.7%, respectively, P = 0.025), and 100% contraction rate tended to be higher in the vonoprazan group relative to the esomeprazole group (32% vs 13%, respectively, P = 0.070).

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Patients evaluated incompetent by doctors in attendance

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The rate of the stage of scar at 4 weeks after endoscopic submucosal dissection (ESD) for gastric adenoma/carcinoma (comparison of vonoprazan and esomeprazole as historical control group)
Secondary Outcome Measures
NameTimeMethod
The diameter of the ulcer at 4 weeks after endoscopic submucosal dissection (ESD) for gastric adenoma/carcinoma and relationship between these and patients background or lesion information (comparison of vonoprazan and esomeprazole as historical control group)
© Copyright 2025. All Rights Reserved by MedPath